Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Application
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
Novel Approaches of gene therapy
4.1.2. Restraints
4.1.2.1. High cost of gene therapy treatment
4.1.3. Opportunity
4.1.3.1. Rise in the strategic acquisition and partnership among the organizations
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Therapy
7.1 Somatic Gene Therapy
7.2 Germline Therapy
8. By Drug Class
8.1. Cardiology
8.2. Neurology
8.3. Oncology
8.4. Infectious Diseases
8.5. Inherited Diseases
8.6. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. The U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. The UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Gilead Sciences
11.3. Jazz Pharmaceuticals
11.4. Orchard Therapeutics
11.5. Bristol-Myers Squibb
11.6. Amgen
11.7. SiBiono Genentech,
11.8. Shanghai Sunway Biotech Co
11.9. Adapt Immune Therapeutics
11.10. Adverum Biotechnologies
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us